^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    abiraterone decanoate (ASP5541)

    i
    Other names: ASP5541, PRL-02
    Associations

    News

    Trials
    Company:
    Astellas
    Drug class:
    CYP17A1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    Phase 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate, in patients with prostate cancer including those previously treated with enzalutamide. (ASCO-GU 2024)
    PRL-02 was well tolerated. The RP2D of 1260 mg was selected over 1800 mg due to the absence of progesterone rises at 1260 mg. PRL-02 produces durable dose dependent T suppression and associated PSA response.
    Clinical • P1/2 data
    |
    Xtandi (enzalutamide capsule) • abiraterone decanoate (ASP5541)
    over3years
    Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer (clinicaltrials.gov)
    P1/2, N=45, Not yet recruiting, Propella Therapeutics
    Clinical • New P1/2 trial
    |
    ALB (Albumin)
    |
    abiraterone decanoate (ASP5541)